The combination of impaired epithelial barrier function, mucosal inflammation and elevated oxidative stress is determinant for the pathogenesis of ulcerative colitis (UC). NF-E2-related factor 2 (NRF2) is an important transcription factor for modulating antioxidant defenses, inhibiting inflammatory pathways and regenerating the epithelial barrier. Montai Therapeutics Inc. has developed a potent and selective NRF2 agonist compound, MTAI-1025, for the management of UC using its proprietary CONECTA platform.
Addex Therapeutics Ltd. has released preclinical data demonstrating antitussive activity of its γ-aminobutyric acid subtype B receptor (GABA-B) positive allosteric modulator (PAM) candidate in a bleomycin-induced idiopathic pulmonary fibrosis (IPF)-exacerbated chronic cough model.
Rett syndrome (RTT) is a rare neurodevelopmental condition affecting multiple organ systems and is most often driven by mutations in the X-linked MECP2 gene. Researchers at Shanghai Duomirui Biological Technology Co. Ltd. have developed a new class of trofinetide prodrugs aimed at addressing limitations related to drug administration and pharmacokinetic properties.
Acurastem Inc. has been awarded $7.5 million in grant funding by the California Institute for Regenerative Medicine (CIRM) to support the advancement of lead clinical candidate AS-241 toward first-in-human testing.
T-cell engagers (TCEs) drive synthetic antitumor immunity by bypassing endogenous T-cell priming and directly inducing tumor cell killing. In prostate cancer, targeting prostate-restricted antigens such as STEAP2, combined with CD8-guided TCE formats that favor cytotoxic T-cell engagement, offers a strategy to reduce cytokine release while maintaining antitumor activity.
Evolveimmune Therapeutics Inc. has announced the nomination of a development candidate against a solid tumor target as part of its ongoing partnership with Abbvie Inc., triggering an $18 million milestone payment to Evolveimmune.
Aventera Antibodies AB has successfully raised SEK14.5 million (US$15.6 million) in a funding round to support the preclinical development of the company’s lead drug candidate for life-threatening streptococcal infections.
Cervical cancer (CaCx) remains one of the most frequent female malignancies, causing over 300,000 deaths every year. Persistent infection with high-risk human papillomaviruses (HPV), particularly HPV16 and HPV18 strains, drives oncogenesis and tumor maintenance through continual expression of HPV oncogenes E6 and E7. A potential strategy to overcome limitations of current treatments is the development of targeted therapies that exploit alterations in gene expression in CaCx.
A joint Ajax Therapeutics Inc. and Dana-Farber Cancer Institute Inc. patent divulges new JAK2 degradation inducers intended for use in the treatment of polycythemia vera, myeloid leukemia and essential thrombocythemia.
Pfizer Inc. has discovered new gastric inhibitory polypeptide receptor (GIPR) antagonists potentially useful for the treatment of type 2 diabetes and obesity.
RSS
